Altimmune (NASDAQ:ALT) Third Quarter 2024 Results
Key Financial Results
- Net loss: US$22.8m (loss widened by 11% from 3Q 2023).
- US$0.32 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Altimmune Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates. Earnings per share (EPS) also surpassed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 30% from a week ago.
Risk Analysis
Before you take the next step you should know about the 4 warning signs for Altimmune (1 doesn't sit too well with us!) that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:ALT
Altimmune
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
Flawless balance sheet slight.
